Bayer HealthCare and the World Health Organization (WHO) have been partners for years in the fight against Chagas disease. In March 2011 the company has signed an extension of its agreement with the World Health Organization (WHO) to fight the parasitic infection. The five-year extension will come into effect in April 2012, when the previous agreement signed in 2007 has been set to expire.
By prematurely concluding the agreement one year before expiration, Bayer HealthCare underlines its commitment to its successful collaboration with WHO and ensures that ongoing projects and initiatives can continue beyond the initial timeline. Bayer HealthCare has also committed to doubling its initial donation of 2.5 million Lampit™ tablets (active ingredient: nifurtimox) for the treatment of Chagas disease to a total of 5 million by 2017. In addition, the company will contribute 1.5 million US dollars in cash to fund logistics and distribution.